Cryoport (CYRX) Competitors $7.15 +0.49 (+7.36%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CYRX vs. ZNTL, IRWD, IGMS, AUPH, IRON, RCUS, EVO, TVTX, GYRE, and KURAShould you be buying Cryoport stock or one of its competitors? The main competitors of Cryoport include Zentalis Pharmaceuticals (ZNTL), Ironwood Pharmaceuticals (IRWD), IGM Biosciences (IGMS), Aurinia Pharmaceuticals (AUPH), Disc Medicine (IRON), Arcus Biosciences (RCUS), Evotec (EVO), Travere Therapeutics (TVTX), Gyre Therapeutics (GYRE), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical preparations" industry. Cryoport vs. Zentalis Pharmaceuticals Ironwood Pharmaceuticals IGM Biosciences Aurinia Pharmaceuticals Disc Medicine Arcus Biosciences Evotec Travere Therapeutics Gyre Therapeutics Kura Oncology Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Cryoport (NASDAQ:CYRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk. Do analysts rate ZNTL or CYRX? Zentalis Pharmaceuticals presently has a consensus price target of $10.78, indicating a potential upside of 224.63%. Cryoport has a consensus price target of $12.00, indicating a potential upside of 67.83%. Given Zentalis Pharmaceuticals' higher possible upside, equities analysts plainly believe Zentalis Pharmaceuticals is more favorable than Cryoport.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zentalis Pharmaceuticals 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30Cryoport 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has stronger earnings & valuation, ZNTL or CYRX? Cryoport has higher revenue and earnings than Zentalis Pharmaceuticals. Cryoport is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZentalis PharmaceuticalsN/AN/A-$292.19M-$2.72-1.22Cryoport$233.26M1.51-$99.59M-$3.67-1.95 Does the media refer more to ZNTL or CYRX? In the previous week, Cryoport had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 3 mentions for Cryoport and 1 mentions for Zentalis Pharmaceuticals. Cryoport's average media sentiment score of 0.39 beat Zentalis Pharmaceuticals' score of 0.00 indicating that Cryoport is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cryoport 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in ZNTL or CYRX? Cryoport received 183 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. Likewise, 64.86% of users gave Cryoport an outperform vote while only 62.64% of users gave Zentalis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformZentalis PharmaceuticalsOutperform Votes5762.64% Underperform Votes3437.36% CryoportOutperform Votes24064.86% Underperform Votes13035.14% Do institutionals and insiders hold more shares of ZNTL or CYRX? 92.9% of Cryoport shares are owned by institutional investors. 3.6% of Zentalis Pharmaceuticals shares are owned by insiders. Comparatively, 10.1% of Cryoport shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, ZNTL or CYRX? Zentalis Pharmaceuticals has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Is ZNTL or CYRX more profitable? Zentalis Pharmaceuticals has a net margin of 0.00% compared to Cryoport's net margin of -76.48%. Cryoport's return on equity of -15.55% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Zentalis PharmaceuticalsN/A -44.22% -35.61% Cryoport -76.48%-15.55%-7.41% SummaryCryoport beats Zentalis Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Ad Paradigm PressEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Get Cryoport News Delivered to You Automatically Sign up to receive the latest news and ratings for CYRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYRX vs. The Competition Export to ExcelMetricCryoportPharmaceutical IndustryTransportation SectorNASDAQ ExchangeMarket Cap$353.28M$7.42B$318.91B$8.53BDividend YieldN/A7.96%4.44%4.14%P/E Ratio-1.959.9313.8415.14Price / Sales1.51396.6349.24100.10Price / Cash17.4147.3912.9734.08Price / Book0.765.322.095.02Net Income-$99.59M$153.56M$564.17M$225.46M7 Day Performance3.77%0.13%-1.03%0.37%1 Month Performance-15.08%15.23%-2.01%3.57%1 Year Performance-25.98%41.14%16.48%29.43% Cryoport Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYRXCryoport2.515 of 5 stars$7.15+7.4%$12.00+67.8%-24.9%$353.28M$233.26M-1.951,170Upcoming EarningsShort Interest ↑News CoverageZNTLZentalis Pharmaceuticals1.5732 of 5 stars$3.32+21.6%$10.78+224.6%-79.7%$194.12MN/A-1.22160Upcoming EarningsHigh Trading VolumeIRWDIronwood Pharmaceuticals4.7747 of 5 stars$4.19+6.1%$12.17+190.4%-53.8%$669.31M$400.57M104.75220Upcoming EarningsGap UpIGMSIGM Biosciences3.7141 of 5 stars$16.22-5.4%$15.00-7.5%+286.2%$962.17M$2.13M-4.42190Short Interest ↓Gap UpAUPHAurinia Pharmaceuticals2.3482 of 5 stars$7.32+1.5%$10.00+36.6%+2.7%$1.05B$175.51M-21.53300Upcoming EarningsNews CoverageIRONDisc Medicine3.7671 of 5 stars$47.13+5.2%$66.40+40.9%+2.5%$1.40BN/A-12.8478Short Interest ↓RCUSArcus Biosciences2.7286 of 5 stars$15.50+1.3%$33.67+117.2%-2.0%$1.40B$247M-5.02500Upcoming EarningsEVOEvotec2.5238 of 5 stars$3.88+0.3%$5.93+52.9%-54.8%$1.37B$845.74M0.005,061Upcoming EarningsHigh Trading VolumeTVTXTravere Therapeutics2.1449 of 5 stars$17.57+0.4%$21.85+24.3%+161.5%$1.34B$145.24M-3.86460Earnings ReportAnalyst ForecastGap UpGYREGyre TherapeuticsN/A$14.47+1.2%N/AN/A$1.34B$113.45M0.0040Upcoming EarningsKURAKura Oncology4.1349 of 5 stars$16.88+1.0%$28.83+70.8%+111.3%$1.29BN/A-7.57142Upcoming EarningsShort Interest ↓ Related Companies and Tools Related Companies Zentalis Pharmaceuticals Competitors Ironwood Pharmaceuticals Competitors IGM Biosciences Competitors Aurinia Pharmaceuticals Competitors Disc Medicine Competitors Arcus Biosciences Competitors Evotec Competitors Travere Therapeutics Competitors Gyre Therapeutics Competitors Kura Oncology Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYRX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cryoport, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cryoport With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
